Wordt geladen...
Single dose denileukin diftitox does not enhance vaccine-induced T cell responses or effectively deplete Tregs in advanced melanoma: immune monitoring and clinical results of a randomized phase II trial
BACKGROUND: Depletion of CD25(+) Tregs improves anti-tumor immunity in preclinical models. Denileukin diftitox is a recombinant fusion protein of human IL-2 and diptheria toxin fragment that also can kill CD25(+) T cells. Prior clinical trials of denileukin diftitox suggested reduction of FoxP3(+) T...
Bewaard in:
| Gepubliceerd in: | J Immunother Cancer |
|---|---|
| Hoofdauteurs: | , , , |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
BioMed Central
2016
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4915048/ https://ncbi.nlm.nih.gov/pubmed/27330808 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40425-016-0140-2 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|